HRP20180109T1 - Inhibitori gsk-3 - Google Patents
Inhibitori gsk-3 Download PDFInfo
- Publication number
- HRP20180109T1 HRP20180109T1 HRP20180109TT HRP20180109T HRP20180109T1 HR P20180109 T1 HRP20180109 T1 HR P20180109T1 HR P20180109T T HRP20180109T T HR P20180109TT HR P20180109 T HRP20180109 T HR P20180109T HR P20180109 T1 HRP20180109 T1 HR P20180109T1
- Authority
- HR
- Croatia
- Prior art keywords
- disease
- substituted
- unsubstituted
- compound
- use according
- Prior art date
Links
- 101150090422 gsk-3 gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 10
- 206010012289 Dementia Diseases 0.000 claims 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 208000027089 Parkinsonian disease Diseases 0.000 claims 4
- 206010034010 Parkinsonism Diseases 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 claims 3
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 208000029028 brain injury Diseases 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 206010065040 AIDS dementia complex Diseases 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 2
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010061598 Immunodeficiency Diseases 0.000 claims 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 2
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 230000000740 bleeding effect Effects 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000037976 chronic inflammation Diseases 0.000 claims 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 206010014599 encephalitis Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 208000024963 hair loss Diseases 0.000 claims 2
- 230000003676 hair loss Effects 0.000 claims 2
- 206010020718 hyperplasia Diseases 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 230000007813 immunodeficiency Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 201000002364 leukopenia Diseases 0.000 claims 2
- 231100001022 leukopenia Toxicity 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000000626 neurodegenerative effect Effects 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 2
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 238000011084 recovery Methods 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000004720 cerebrum Anatomy 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/66—Nitrogen atoms not forming part of a nitro radical
Claims (15)
1. Upotreba spoja formule (I)
[image]
,
ili bilo koje njegove farmaceutski prihvatljive soli ili solvata, gdje:
RB je skupina koju se bira između
[image]
;
R3, R4, R’2, R’3, R’4, R’5 i R’6 se bira između vodika, supstituiranog ili nesupstituiranog alkila, supstituiranog ili nesupstituiranog cikloalkila, supstituiranog ili nesupstituiranog alkenila, supstituiranog ili nesupstituiranog arila, supstituiranog ili nesupstituiranog heterocikla, -C(=O)R7, -C(=O)OR8, -C(=O)NR9R10, -C=NR11, -CN, -OR12, -OC(=O)R13, -S(O)t-R14,-NR15R16, -NR17C(=O)R18, -NO2, -N=CR19R20 ili halogena, gdje R3 i R4 zajedno mogu tvoriti skupinu =O, te gdje bilo koji par kojeg čine R3R’2, R3R’6, R4R’2, R4R’6, R’2R’3, R’3R’4, R’4R’5, R’5R’6, R15R16, R17R18 ili R19R20 može zajedno tvoriti prstenasti supstituent;
t je 0, 1, 2, 3;
R7, R8, R9, R10, R11, R13, R14, R15, R16, R17, R18, R19 i R20 se bira između vodika, supstituiranog ili nesupstituiranog alkila, supstituiranog ili nesupstituiranog cikloalkila, supstituiranog ili nesupstituiranog alkenila, supstituiranog ili nesupstituiranog arila, supstituiranog ili nesupstituiranog heterocikla, supstituiranog ili nesupstituiranog alkoksi, supstituiranog ili nesupstituiranog ariloksi, halogena;
R12 se bira između vodika, nesupstituiranog alkila, supstituiranog ili nesupstituiranog cikloalkila, supstituiranog ili nesupstituiranog alkenila, supstituiranog ili nesupstituiranog arila, supstituiranog ili nesupstituiranog heterocikla, halogena;
naznačena time što je spoj namijenjen proizvodnji medikamenta za liječenje i/ili sprječavanje bolesti ili stanja povezanog s GSK-3, gdje se bolest ili stanje bira iz skupine koju čine dijabetes, stanja povezana s dijabetesom, kronična neurodegenerativna stanja, uključujući demencije, poput Alzheimerove bolesti, Parkinsonove bolesti, progresivne supranuklearne paralize, subakutnog sklerozirajućeg panencefalitičkog parkinsonizma, postencefalitičkog parkinsonizma, pugilističkog encefalitisa, guamskog kompleksa parkinsonizma s demencijom, Pickove bolesti, kortikobazalne degeneracije, frontotemporalne demencije, Huntingtonove bolesti, demencije povezane s AIDS-om, amiotrofna lateralne skleroze, multiple skleroze i neurotraumatske bolesti, poput akutnog inzulta, epilepsije, poremećaji raspoloženja, poput depresije, shizofrenije i bipolarnih poremećaja, poticanje funkcionalnog oporavka nakon inzulta, krvarenje u velikom mozgu, primjerice zbog pojedinačne cerebralne amiloidne angiopatije, gubitak kose, pretilost, hipertenzija, sindrom policističnih jajnika, sindrom X, ishemija, ozljeda mozga, traumatska ozljeda mozga, rak, leukopenija, Downov sindrom, bolest Lewyjevih tijela, upala, kronične upalne bolesti, rak i hiperproliferativne bolesti poput hiperplazija i imunodeficijencija.
2. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što su R3 i R4 H.
3. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što se R’2, R’3, R’4, R’5 i R’6 bira između vodika, supstituiranog ili nesupstituiranog alkila, -C(=O)R7, -C(=O)OR8, -OR12, -NR15R16 ili halogena, gdje su R7, R8, R12, R15 i R16 definirani kao u patentnom zahtjevu 1.
4. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što su R’2, R’3, R’4, R’5 i R’6 H.
5. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što se spoj formule (I) bira između:
[image]
6. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što je bolest Alzheimerova bolest.
7. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što je bolest dijabetes tip II.
8. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što je bolest depresija.
9. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što je bolest ozljeda mozga.
10. Spoj, naznačen time što je spoj formule
[image]
.
11. Spoj formule
[image]
,
naznačen time što je namijenjen upotrebi kao medikament.
12. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 10 do 11, kao i farmaceutski prihvatljivu podlogu, adjuvans ili vehikulum.
13. Farmaceutski pripravak u skladu s patentnim zahtjevom 12, naznačen time što je namijenjen oralnoj primjeni.
14. Upotreba spoja formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačena time što se spoj upotrebljava kao reagens za inhibiranje GSK-3 u biološkim ispitivanjima.
15. Spoj formule (I) u skladu s patentnim zahtjevima 1 do 5, ili njegov farmaceutski pripravak, naznačeni time što su namijenjeni upotrebi u liječenju ili sprječavanju bolesti ili stanja povezanog s GSK-3, gdje se bolest ili stanje bira iz skupine koju čine dijabetes, stanja povezana s dijabetesom, kronična neurodegenerativna stanja, uključujući demencije, poput Alzheimerove bolesti, Parkinsonove bolesti, progresivne supranuklearne paralize, subakutnog sklerozirajućeg panencefalitičkog parkinsonizma, postencefalitičkog parkinsonizma, pugilističkog encefalitisa, guamskog kompleksa parkinsonizma s demencijom, Pickove bolesti, kortikobazalne degeneracije, frontotemporalne demencije, Huntingtonove bolesti, demencije povezane s AIDS-om, amiotrofna lateralne skleroze, multiple skleroze i neurotraumatske bolesti, poput akutnog inzulta, epilepsije, poremećaji raspoloženja, poput depresije, shizofrenije i bipolarnih poremećaja, poticanje funkcionalnog oporavka nakon inzulta, krvarenje u velikom mozgu, primjerice zbog pojedinačne cerebralne amiloidne angiopatije, gubitak kose, pretilost, hipertenzija, sindrom policističnih jajnika, sindrom X, ishemija, ozljeda mozga, traumatska ozljeda mozga, rak, leukopenija, Downov sindrom, bolest Lewyjevih tijela, upala, kronične upalne bolesti, rak i hiperproliferativne bolesti poput hiperplazija i imunodeficijencija.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05380176A EP1749523A1 (en) | 2005-07-29 | 2005-07-29 | GSK-3 inhibitors |
| PCT/EP2006/007520 WO2007017145A2 (en) | 2005-07-29 | 2006-07-28 | Gsk-3 inhibitors |
| EP06776492.8A EP1919465B1 (en) | 2005-07-29 | 2006-07-28 | Gsk-3 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180109T1 true HRP20180109T1 (hr) | 2018-04-20 |
Family
ID=35445902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180109TT HRP20180109T1 (hr) | 2005-07-29 | 2018-01-22 | Inhibitori gsk-3 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8686042B2 (hr) |
| EP (2) | EP1749523A1 (hr) |
| JP (1) | JP5484726B2 (hr) |
| KR (1) | KR101471999B1 (hr) |
| CN (1) | CN101257900B (hr) |
| AU (1) | AU2006278829B2 (hr) |
| BR (1) | BRPI0615968B1 (hr) |
| CA (1) | CA2616451C (hr) |
| CY (1) | CY1119971T1 (hr) |
| DK (1) | DK1919465T3 (hr) |
| ES (1) | ES2661326T3 (hr) |
| HK (1) | HK1124761A1 (hr) |
| HR (1) | HRP20180109T1 (hr) |
| HU (1) | HUE036844T2 (hr) |
| IL (1) | IL189048A (hr) |
| LT (1) | LT1919465T (hr) |
| NO (1) | NO341454B1 (hr) |
| NZ (1) | NZ566380A (hr) |
| PL (1) | PL1919465T3 (hr) |
| PT (1) | PT1919465T (hr) |
| RU (1) | RU2449998C2 (hr) |
| SI (1) | SI1919465T1 (hr) |
| WO (1) | WO2007017145A2 (hr) |
| ZA (1) | ZA200800983B (hr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8642598B2 (en) | 2006-10-21 | 2014-02-04 | Abbvie Inc. | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors |
| WO2009098287A1 (en) * | 2008-02-06 | 2009-08-13 | Noscira S.A. | Phenyl-prenyl derivatives, of marine and synthetic origin, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders |
| EP2262498A2 (en) * | 2008-03-10 | 2010-12-22 | Vertex Pharmceuticals Incorporated | Pyrimidines and pyridines useful as inhibitors of protein kinases |
| CA2720659C (en) * | 2008-04-24 | 2016-10-18 | Abbott Gmbh & Co. Kg | 1-(7-(hexahydropyrrolo[3,4-c]pyrrol-2(1h)-yl)quinolin-4-yl)-3-(pyrazin-2-yl)urea derivatives and related compounds as glycogen synthase kinase 3 (gsk-3) |
| PE20120508A1 (es) | 2009-06-17 | 2012-05-09 | Vertex Pharma | Inhibidores de la replicacion de los virus de la gripe |
| CA2810954A1 (en) | 2010-09-27 | 2012-04-05 | Abbott Gmbh & Co. Kg | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| WO2013173206A1 (en) * | 2012-05-14 | 2013-11-21 | University Of Kansas | Phosphonate derivatives for treatment of alzheimer's disease |
| NZ713219A (en) | 2013-03-14 | 2017-04-28 | Massachusetts Inst Technology | Compositions and methods for epithelial stem cell expansion and culture |
| EP3068776B1 (en) | 2013-11-13 | 2019-05-29 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| SG10201804021TA (en) | 2013-11-13 | 2018-07-30 | Vertex Pharma | Methods of preparing inhibitors of influenza viruses replication |
| CN107073042A (zh) | 2014-09-03 | 2017-08-18 | 布里格海姆妇女医院公司 | 用于产生内耳毛细胞来治疗听力损失的组合物、***和方法 |
| JP6857617B2 (ja) | 2015-05-13 | 2021-04-14 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | インフルエンザウイルスの複製の阻害剤 |
| WO2016183116A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
| EP3400286A1 (en) | 2016-01-08 | 2018-11-14 | Massachusetts Institute Of Technology | Production of differentiated enteroendocrine cells and insulin producing cells |
| US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
| CN106727556B (zh) * | 2016-11-30 | 2017-10-20 | 鑫喆喆 | 一种治疗脑损伤的药物组合物 |
| KR20190104359A (ko) | 2016-12-30 | 2019-09-09 | 프리퀀시 테라퓨틱스, 인크. | 줄기/전구체 지지 세포의 자가 재생을 유도하기 위한 1h-피롤-2,5-다이온 화합물 및 이의 사용 방법 |
| JP2021533788A (ja) | 2018-08-17 | 2021-12-09 | フリークエンシー セラピューティクス インコーポレイテッド | Ｊａｇ−１を上方制御することにより有毛細胞を生成するための組成物及び方法 |
| US11617745B2 (en) | 2018-08-17 | 2023-04-04 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating FOXO |
| US20220133740A1 (en) | 2019-02-08 | 2022-05-05 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
| CN117186027B (zh) * | 2023-09-11 | 2024-04-19 | 上海蓝木化工有限公司 | 一种糖原合酶激酶-3抑制剂及其制备方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB895625A (en) * | 1957-12-27 | 1962-05-02 | Hoechst Ag | New benzene-sulphonyl benzyl-ureas and process of preparing them |
| ES474449A1 (es) * | 1978-10-23 | 1979-05-01 | Invest Tecnica Aplicada | Procedimiento de obtencion de ureas y tioureas con actividad farmacologica. |
| EP0131071B1 (en) * | 1983-01-24 | 1987-05-13 | Duphar International Research B.V | Benzoylurea compounds, and pesticidal and pharmaceutical compositions comprising same |
| JPH10182588A (ja) * | 1996-10-30 | 1998-07-07 | Ss Pharmaceut Co Ltd | 置換ベンジル尿素誘導体及びこれを含有する医薬 |
| US5922767A (en) * | 1996-10-30 | 1999-07-13 | Ss Pharmaceutical Co., Ltd. | Substituted benzylurea derivatives and medicine containing the same |
| US6071934A (en) * | 1997-03-25 | 2000-06-06 | Cell Pathways, Inc. | Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions |
| NZ504124A (en) * | 1997-11-07 | 2002-10-25 | Schering Corp | Phenyl-alkyl-imidazoles and use in treating inflammatory disease |
| PE20000942A1 (es) | 1998-07-31 | 2000-09-28 | Lilly Co Eli | Derivados de amida, carbamato y urea |
| EP1274415A4 (en) * | 2000-03-14 | 2005-09-07 | Smithkline Beecham Corp | IL-8 RECEPTOR ANTAGONISTS |
| US6900041B2 (en) * | 2000-10-02 | 2005-05-31 | Reddy Us Therapeutics Inc. | Methods and compositions for the treatment of inflammatory diseases |
| SE0102438D0 (sv) * | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| SE0102439D0 (sv) * | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| SE0102440D0 (sv) * | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compound |
| AR039209A1 (es) * | 2002-04-03 | 2005-02-09 | Novartis Ag | Derivados de indolilmaleimida |
| SE0201194D0 (sv) * | 2002-04-19 | 2002-04-19 | Astrazeneca Ab | New compounds |
| AU2003288899B2 (en) * | 2002-08-23 | 2009-09-03 | Novartis Vaccines And Diagnostics, Inc. | Benzimidazole quinolinones and uses thereof |
| TWI372050B (en) * | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| EP1493438A1 (en) * | 2003-07-03 | 2005-01-05 | Bayer HealthCare AG | Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states |
| EP1586318A1 (en) * | 2004-04-05 | 2005-10-19 | Neuropharma S.A.U. | Thiadiazolidinones as GSK-3 inhibitors |
-
2005
- 2005-07-29 EP EP05380176A patent/EP1749523A1/en not_active Withdrawn
-
2006
- 2006-07-28 PL PL06776492T patent/PL1919465T3/pl unknown
- 2006-07-28 EP EP06776492.8A patent/EP1919465B1/en active Active
- 2006-07-28 HU HUE06776492A patent/HUE036844T2/hu unknown
- 2006-07-28 ZA ZA200800983A patent/ZA200800983B/xx unknown
- 2006-07-28 NZ NZ566380A patent/NZ566380A/en active IP Right Revival
- 2006-07-28 LT LTEP06776492.8T patent/LT1919465T/lt unknown
- 2006-07-28 CN CN2006800275243A patent/CN101257900B/zh active Active
- 2006-07-28 DK DK06776492.8T patent/DK1919465T3/en active
- 2006-07-28 ES ES06776492.8T patent/ES2661326T3/es active Active
- 2006-07-28 BR BRPI0615968-0A patent/BRPI0615968B1/pt active IP Right Grant
- 2006-07-28 CA CA2616451A patent/CA2616451C/en active Active
- 2006-07-28 RU RU2008107733/04A patent/RU2449998C2/ru active
- 2006-07-28 US US11/996,962 patent/US8686042B2/en active Active
- 2006-07-28 WO PCT/EP2006/007520 patent/WO2007017145A2/en active Application Filing
- 2006-07-28 AU AU2006278829A patent/AU2006278829B2/en active Active
- 2006-07-28 SI SI200632241T patent/SI1919465T1/en unknown
- 2006-07-28 JP JP2008523261A patent/JP5484726B2/ja active Active
- 2006-07-28 PT PT67764928T patent/PT1919465T/pt unknown
-
2008
- 2008-01-27 IL IL189048A patent/IL189048A/en active IP Right Grant
- 2008-02-21 KR KR1020087004188A patent/KR101471999B1/ko active IP Right Grant
- 2008-02-28 NO NO20081052A patent/NO341454B1/no unknown
-
2009
- 2009-03-03 HK HK09101997.2A patent/HK1124761A1/xx unknown
-
2018
- 2018-01-22 HR HRP20180109TT patent/HRP20180109T1/hr unknown
- 2018-02-22 CY CY20181100217T patent/CY1119971T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180109T1 (hr) | Inhibitori gsk-3 | |
| HRP20100032T1 (hr) | Tiadiazolidinoni kao inhibitori gsk-3 | |
| AU2018201060B2 (en) | 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto | |
| JP2019520417A5 (hr) | ||
| JP2007531782A5 (hr) | ||
| CN104086540B (zh) | 5,6‑二氢‑1h‑吡啶‑2‑酮化合物的制备方法 | |
| AR020727A1 (es) | Uso de compuestos derivados 3-amino-4-aril-maleimidas para la preparacion de medicamentos para condiciones asociadas a una necesidad de inhibicion de lagsk-3, dichos compuestos, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden | |
| HRP20170531T1 (hr) | Novi terapijski pristupi za liječenje alzheimerove bolesti i povezanih poremećaja putem modulacije angiogeneze | |
| JP2008524328A5 (hr) | ||
| JP2007533740A5 (hr) | ||
| ES2606043T3 (es) | Derivados de biarilo como moduladores de nAChR | |
| JP2017512833A5 (hr) | ||
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| RU2008146995A (ru) | N-(2-тиазолил)амидные производные в качестве ингибиторов gsk-3 | |
| RU2004114263A (ru) | Производные тиазола, имеющие антагонистичекую агонистическую или частично агонистическую св1-активность | |
| JP2013519685A5 (hr) | ||
| RU2011137419A (ru) | Обратные агонисты и антагонисты гистамина н3 и способы их применения | |
| JP2018523665A5 (hr) | ||
| AR069524A1 (es) | Derivados de isoxazolo - pirazina, un procedimiento para la preparacion del compuesto, medicamento en base al compuesto y uso del compuesto para preparar un medicamento | |
| AR068888A1 (es) | Derivados de 1, 3, 4 - tiadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la quinesina ksp. | |
| JP2020502092A5 (hr) | ||
| AR066641A1 (es) | Amidas disustituidas para mejorar las respuestas sinapticas glutamatergicas | |
| ECSP14013221A (es) | Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento. | |
| JP2017508816A5 (hr) | ||
| TW200840572A (en) | 5,6-dihydro-1H-pyridin-2-one compounds |